Business context and reporting period
Koninklijke Philips N.V. filed this Form 20-F on February 26, 2019, reporting audited results for the fiscal year ended December 31, 2018. Although the request references 2018 Q4, this filing is an annual report and does not provide a standalone fourth-quarter financial summary. The consolidated statements are prepared under IFRS.
Philips is a health technology company, reporting 2018 results across Diagnosis & Treatment, Connected Care & Health Informatics, Personal Health, and Other. Signify (formerly Philips Lighting) was deconsolidated in 2017 and was no longer a significant influence investment as of December 31, 2018.
Key financial metrics
| Metric | 2018 | 2017 | Change / context |
|---|---|---|---|
| Sales | €18.121 billion | €17.780 billion | +1.9% nominal; +4.7% comparable (management rounded to 5%) |
| Gross margin | €8.554 billion; 47.2% of sales | €8.181 billion; 46.0% | Margin up 1.2 percentage points |
| Income from operations | €1.719 billion; 9.5% of sales | €1.517 billion; 8.5% | Up €202 million |
| Adjusted EBITA | €2.366 billion; 13.1% of sales | €2.153 billion; 12.1% | Up €213 million; margin up 100 basis points. Non-IFRS measure. |
| Income from continuing operations | €1.310 billion | €1.028 billion | Up €282 million |
| Net income | €1.097 billion | €1.870 billion | Down €773 million, primarily reflecting Signify-related discontinued operations |
| Operating cash flow | €1.780 billion | €1.870 billion | Down €90 million; higher working-capital outflows offset higher earnings |
| Free cash flow | €984 million | €1.185 billion | Includes €176 million outflow for pension de-risking and early bond redemption. Non-IFRS measure. |
| Cash and cash equivalents | €1.688 billion | €1.939 billion | Down €251 million |
| Total debt / net debt | €4.821 billion / €3.132 billion | €4.715 billion / €2.776 billion | Net debt increased €356 million |
| Shareholders’ equity | €12.088 billion | €11.999 billion | Up €89 million |
At year-end, Philips reported €2.688 billion of available liquidity, including cash and a €1 billion committed revolving facility, against gross debt of €4.821 billion. The facility was undrawn. Credit ratings were A- (Fitch), Baa1 (Moody’s), and BBB+ (S&P), each with stable outlook; outstanding long-term debt has no financial covenants. Research and development expense was €1.759 billion, or 9.7% of sales.
Material changes versus the prior comparable period
- Comparable sales growth was 4.7% (reported as 5%), versus 3.9% in 2017. Diagnosis & Treatment grew 6.8% comparably; Personal Health grew 3.3%; Connected Care & Health Informatics was up 0.3%.
- Adjusted EBITA margin rose to 13.1% from 12.1%, reflecting growth, operational improvements and higher IP royalty income. Productivity programs generated about €466 million in annual savings, ahead of the €400 million target.
- Net income fell despite higher continuing-operations income. Discontinued operations recorded a €213 million loss in 2018, including a €218 million value adjustment on Philips’ retained Signify interest; 2017 included a gain on Signify’s deconsolidation.
- Personal Health had slower performance, which management partly attributed to internal execution challenges. Connected Care & Health Informatics had flat comparable sales; Diagnosis & Treatment delivered the strongest segment growth and earnings improvement.
Guidance, outlook, commentary, risks and unusual items
Management reiterated medium-term targets for 2017–2020: 4–6% annual comparable sales growth, average annual Adjusted EBITA margin improvement of 100 basis points, and annual free cash flow above €1.5 billion by 2020. The filing does not provide a specific 2019 revenue or profit forecast. Management cited geopolitical and macroeconomic uncertainty, trade tariffs, emerging-market currency volatility and procurement pressures, while describing actions to mitigate these headwinds.
- Quality and regulatory matters: A US consent decree restricts manufacture and distribution in the US of certain external defibrillators made at specified facilities, subject to exceptions, pending FDA certification. Philips reported €56 million of consent-decree charges in 2018; the filing says future costs and the matter’s ultimate impact are uncertain. The company also expects a one-time €45 million EU Medical Device Regulation investment in 2019, plus approximately €25 million in annual ongoing compliance costs.
- Legal and regulatory contingencies: Philips disclosed continuing CRT antitrust claims for which potential losses could not be reliably estimated, a Brazilian investigation into alleged tender irregularities, and US government inquiries concerning certain Respironics financing and sleep-center relationships. A post-year-end claim by LG Electronics sought €64.6 million in connection with the CRT matter. The filing does not quantify a clear potential financial effect for several of these matters.
- Other charges and estimates: 2018 operating results included €258 million of restructuring and acquisition-related charges, €56 million of consent-decree charges, and €18 million of a €30 million provision related to the European Commission retail-pricing investigation conclusion. EPD acquisition contingent consideration was recorded at €239 million at acquisition; total contingent consideration liabilities were €409 million at year-end.
- Signify and capital allocation: Philips held 16.5% of Signify at year-end and reclassified the investment to current financial assets after losing significant influence. A proposed dividend of €0.85 per share (6% higher) was subject to shareholder approval. On January 29, 2019, Philips announced a new share buyback of up to €1.5 billion, expected to be completed within two years.
- Other exposures: The company identifies cybersecurity and data privacy, product quality and safety, supply-chain disruption and component shortages, foreign exchange and interest rates, pensions, tax matters, acquisitions and integration, and the timing and proceeds of the remaining Signify sell-down as risks. Goodwill totaled €8.503 billion; the filing reports no 2018 impairment, but identifies limited headroom and sensitivity for certain smaller cash-generating units.
Ernst & Young issued an unqualified opinion on the consolidated financial statements and internal control over financial reporting. Management and the auditor concluded internal control over financial reporting was effective at December 31, 2018.
Important facts for investors to verify
- Reconcile the reported net-income decline with the €213 million discontinued-operations loss and Signify valuation adjustment; distinguish these from continuing-operations performance.
- Review the quality, regulatory and consent-decree disclosures, including the US manufacturing restrictions, expected compliance spending and any subsequent FDA developments.
- Assess whether Connected Care & Health Informatics can convert its reported order-book expansion into sales growth, and whether Personal Health execution improves.
- Track working capital, free cash flow, debt and liquidity after the 2018 acquisitions, share repurchases, pension funding and bond refinancing.
- Evaluate the assumptions behind the €1.5 billion 2020 free-cash-flow target and the 2017–2020 growth and margin objectives; these are targets, not a specific 2019 forecast.
- Monitor the remaining Signify stake, contingent consideration from acquisitions, unresolved litigation and investigations, and goodwill sensitivity. Non-IFRS measures such as comparable sales growth, Adjusted EBITA and free cash flow should be considered alongside IFRS results.